

# Priority Health Medicare prior authorization form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to:  Medicare Part B  Medicare Part D  
 This request is:  Expedited request  Standard request

Your request will be expedited if you haven't gotten the prescription and Priority Health Medicare determines, or your prescriber tells us, that your life or health may be at risk by waiting.

## Lonsurf<sup>®</sup> (trifluridine and tipiracil)

### Member

Last Name: \_\_\_\_\_ First Name: \_\_\_\_\_  
 ID #: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender: \_\_\_\_\_  
 Primary Care Physician: \_\_\_\_\_  
 Requesting Provider: \_\_\_\_\_ Prov. Phone: \_\_\_\_\_ Prov. Fax: \_\_\_\_\_  
 Provider Address: \_\_\_\_\_  
 Provider NPI: \_\_\_\_\_ Contact Name: \_\_\_\_\_  
 Provider Signature: \_\_\_\_\_ Date: \_\_\_\_\_

### Drug information

New Request  Continuation Request

Drug product:  Lonsurf 15 / 6.14 mg tablet  Lonsurf 20 / 8.19 mg tablet  
 Start date (or date of next dose): \_\_\_\_\_  
 Date of last dose (if applicable): \_\_\_\_\_  
 Dosing frequency: \_\_\_\_\_

### Prior authorization criteria

The following requirements need to be met before this drug is covered by Priority Health Medicare. These requirements have been approved by the Centers for Medicare and Medicaid Services (CMS), but you may ask us for an exception if you believe one or more of these requirements should be waived.

1. Must be used for a medically-accepted indication\*
2. Must have documentation of KRAS mutation status
3. Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
4. Must first try the following therapies:
  - a. Fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy
  - b. Anti-VEGF therapy
  - c. If KRAS wild type, anti-EGFR therapy

### Medically accepted indication\*

This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is *either*:

- approved by the Food and Drug Administration. (That is, the Food and Drug Administration has approved the drug for the diagnosis or condition for which it is being prescribed.)
- — or — supported by certain reference books. (These reference books are the American Hospital Formulary Service Drug Information and the DRUGDEX Information System)

**Priority Health Precertification Documentation**

**A. What condition is this drug being requested for?**

- Metastatic colorectal cancer
- Other – the patient’s condition is: \_\_\_\_\_

**B. Has the patient been previously treated with:**

- Fluoropyrimidine  
Drug: \_\_\_\_\_ Date: \_\_\_\_\_
- Oxaliplatin                      Date: \_\_\_\_\_
- Irinotecan                         Date: \_\_\_\_\_
- Anti-VEGF therapy  
Drug: \_\_\_\_\_ Date: \_\_\_\_\_

**C. What is the patient’s KRAS mutation? (*Documentation of mutation status is required*)**

- Wild-type
- Other – the patient’s mutation is: \_\_\_\_\_

**If KRAS is wild-type, was the member treated with an anti-EGFR therapy?**

- Yes  
Drug: \_\_\_\_\_ Date: \_\_\_\_\_

- No; rationale: \_\_\_\_\_  
\_\_\_\_\_

**D. What is the patient’s ECOG performance status?**

- 0
- 1
- 2
- 3
- 4

**Priority Health Medicare exception request**

**Do you believe one or more of the prior authorization requirements should be waived?**  Yes  No

If yes, you must provide a statement explaining the medical reason why the exception should be approved.

**Would Lonsurf likely be the most effective option for this patient?**

- Yes  No

If yes, please explain why: \_\_\_\_\_

**If the patient is currently using Lonsurf, would changing the patient’s current regimen likely result in adverse effects for the patient?**

- Yes  No

If yes, please explain: \_\_\_\_\_